168 related articles for article (PubMed ID: 28196905)
1. A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer.
Ryu MH; Ryoo BY; Kim TW; Kim SB; Lim HS; Bae KS; Park SR; Jo YW; Cho HJ; Kang YK
Oncologist; 2017 Feb; 22(2):129-e8. PubMed ID: 28196905
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
Hong YS; Kim KP; Lim HS; Bae KS; Ryu MH; Lee JL; Chang HM; Kang YK; Kim H; Kim TW
Invest New Drugs; 2013 Jun; 31(3):616-22. PubMed ID: 22695940
[TBL] [Abstract][Full Text] [Related]
4. Predicting the efficacy of an oral paclitaxel formulation (DHP107) through modeling and simulation.
Lim HS; Bae KS; Jung JA; Noh YH; Hwang AK; Jo YW; Hong YS; Kim K; Lee JL; Park SJ; Kim JE; Kang YK; Kim TW
Clin Ther; 2015 Feb; 37(2):402-17. PubMed ID: 25579984
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.
Shi M; Sun J; Zhou J; Yu H; Yu S; Xia G; Wang L; Teng Y; Liu G; Yu C; Feng J; Shen Y
Invest New Drugs; 2018 Apr; 36(2):269-277. PubMed ID: 28868573
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.
Lee KW; Lee KH; Zang DY; Park YI; Shin DB; Kim JW; Im SA; Koh SA; Yu KS; Cho JY; Jung JA; Bang YJ
Oncologist; 2015 Aug; 20(8):896-7. PubMed ID: 26112004
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
9. A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors.
Kouroussis C; Kakolyris S; Mavroudis D; Androulakis N; Kalbakis K; Agelaki S; Sarra E; Souglakos J; Christodoulakis M; Samonis G; Georgoulias V
Am J Clin Oncol; 2001 Aug; 24(4):404-7. PubMed ID: 11474274
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer.
Hara T; Omura K; Hirano M; Asada Y; Munemoto Y; Sakamoto J
Cancer Chemother Pharmacol; 2007 Apr; 59(5):631-6. PubMed ID: 16924496
[TBL] [Abstract][Full Text] [Related]
11. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer.
Matsuda G; Kunisaki C; Makino H; Fukahori M; Kimura J; Sato T; Oshima T; Nagano Y; Fuii S; Takagawa R; Kosaka T; Ono HA; Akiyama H; Ichikawa Y
Anticancer Res; 2009 Jul; 29(7):2863-7. PubMed ID: 19596975
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
15. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
Kurzrock R; Gabrail N; Chandhasin C; Moulder S; Smith C; Brenner A; Sankhala K; Mita A; Elian K; Bouchard D; Sarantopoulos J
Mol Cancer Ther; 2012 Feb; 11(2):308-16. PubMed ID: 22203732
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study).
Kim SB; Seo JH; Ahn JH; Kim TY; Kang SY; Sohn J; Yang Y; Park KH; Moon YW; Lim S; Kang MJ; Yoon KE; Cho HJ; Lee KS
Ther Adv Med Oncol; 2021; 13():17588359211061989. PubMed ID: 34925553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
